Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies.
Cancer Sci
; 112(4): 1357-1368, 2021 Apr.
Article
em En
| MEDLINE
| ID: mdl-33416209
ABSTRACT
In recent years, the excellent curative effect of CD19-specific chimeric antigen receptor (CAR) T-cell therapy has brought hope to patients with relapsing or refractory B-cell hematological malignancies, however relapse after CAR T-cell infusion has hindered the widespread clinical application of this immunotherapy and targeted antigen-negative relapse has caused widespread concern. Consequently, strategies for increasing targeted antigens have been created. In addition to the most widely applied target, namely CD19, researchers have further explored the possibility of other targets, such as CD20, CD22, CD33, and CD123, and have tested a series of combination antigen CAR T-cell therapies. Here, we summarize the current preclinical and clinical studies of dual-target CAR T cells.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Receptores de Antígenos de Linfócitos T
/
Neoplasias Hematológicas
/
Receptores de Antígenos Quiméricos
/
Antígenos de Neoplasias
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Cancer Sci
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
China